424 related articles for article (PubMed ID: 32666207)
1. Predicting therapies in Japanese hypertrophic cardiomyopathy patients with an implantable cardioverter-defibrillator using the 2014 European Society of Cardiology guidelines.
Nakano M; Kondo Y; Nakano M; Kajiyama T; Miyazawa K; Hayashi T; Ito R; Takahira H; Kobayashi Y
Heart Vessels; 2021 Jan; 36(1):99-104. PubMed ID: 32666207
[TBL] [Abstract][Full Text] [Related]
2. Validation of the 2014 European Society of Cardiology Sudden Cardiac Death Risk Prediction Model Among Various Phenotypes in Japanese Patients With Hypertrophic Cardiomyopathy.
Nakagawa S; Okada A; Nishimura K; Hamatani Y; Amano M; Takahama H; Amaki M; Hasegawa T; Kanzaki H; Kusano K; Yasuda S; Izumi C
Am J Cardiol; 2018 Dec; 122(11):1939-1946. PubMed ID: 30293654
[TBL] [Abstract][Full Text] [Related]
3. Improvement in sudden cardiac death risk prediction by the enhanced American College of Cardiology/American Heart Association strategy in Chinese patients with hypertrophic cardiomyopathy.
Liu J; Wu G; Zhang C; Ruan J; Wang D; Zhang M; Wang L; Yang Y; Li X; Wang Y; Hui R; Zou Y; Kang L; Wang J; Song L
Heart Rhythm; 2020 Oct; 17(10):1658-1663. PubMed ID: 32311532
[TBL] [Abstract][Full Text] [Related]
4. Validation of the 2014 European Society of Cardiology guidelines risk prediction model for the primary prevention of sudden cardiac death in hypertrophic cardiomyopathy.
Vriesendorp PA; Schinkel AF; Liebregts M; Theuns DA; van Cleemput J; Ten Cate FJ; Willems R; Michels M
Circ Arrhythm Electrophysiol; 2015 Aug; 8(4):829-35. PubMed ID: 25922410
[TBL] [Abstract][Full Text] [Related]
5. A validation study of the 2003 American College of Cardiology/European Society of Cardiology and 2011 American College of Cardiology Foundation/American Heart Association risk stratification and treatment algorithms for sudden cardiac death in patients with hypertrophic cardiomyopathy.
O'Mahony C; Tome-Esteban M; Lambiase PD; Pantazis A; Dickie S; McKenna WJ; Elliott PM
Heart; 2013 Apr; 99(8):534-41. PubMed ID: 23339826
[TBL] [Abstract][Full Text] [Related]
6. Appropriate and inappropriate shocks in hypertrophic cardiomyopathy patients with subcutaneous implantable cardioverter-defibrillators: An international multicenter study.
Nazer B; Dale Z; Carrassa G; Reza N; Ustunkaya T; Papoutsidakis N; Gray A; Howell SJ; Elman MR; Pieragnoli P; Ricciardi G; Jacoby D; Frankel DS; Owens A; Olivotto I; Heitner SB
Heart Rhythm; 2020 Jul; 17(7):1107-1114. PubMed ID: 32084597
[TBL] [Abstract][Full Text] [Related]
7. Importance of newer cardiac magnetic resonance-based risk markers for sudden death prevention in hypertrophic cardiomyopathy: An international multicenter study.
Rowin EJ; Maron MS; Adler A; Albano AJ; Varnava AM; Spears D; Marsy D; Heitner SB; Cohen E; Leong KMW; Winters SL; Martinez MW; Koethe BC; Rakowski H; Maron BJ
Heart Rhythm; 2022 May; 19(5):782-789. PubMed ID: 34933112
[TBL] [Abstract][Full Text] [Related]
8. Primary prevention implantable cardioverter-defibrillators in hypertrophic cardiomyopathy-Are there predictors of appropriate therapy?
Weissler-Snir A; Dorian P; Rakowski H; Care M; Spears D
Heart Rhythm; 2021 Jan; 18(1):63-70. PubMed ID: 32800967
[TBL] [Abstract][Full Text] [Related]
9. Assessment of late gadolinium enhancement in hypertrophic cardiomyopathy improves risk stratification based on current guidelines.
Wang J; Yang S; Ma X; Zhao K; Yang K; Yu S; Yin G; Dong Z; Song Y; Cui C; Li J; Wang C; Hao J; Lu M; Chen X; Zhao S
Eur Heart J; 2023 Dec; 44(45):4781-4792. PubMed ID: 37795986
[TBL] [Abstract][Full Text] [Related]
10. Discrepancy between International Guidelines on the Criteria for Primary Prevention of Sudden Cardiac Death in Hypertrophic Cardiomyopathy.
Mattos BPE; Scolari FL; Garbin HI
Arq Bras Cardiol; 2020 Aug; 115(2):197-204. PubMed ID: 32876184
[TBL] [Abstract][Full Text] [Related]
11. The amount of late gadolinium enhancement outperforms current guideline-recommended criteria in the identification of patients with hypertrophic cardiomyopathy at risk of sudden cardiac death.
Freitas P; Ferreira AM; Arteaga-Fernández E; de Oliveira Antunes M; Mesquita J; Abecasis J; Marques H; Saraiva C; Matos DN; Rodrigues R; Cardim N; Mady C; Rochitte CE
J Cardiovasc Magn Reson; 2019 Aug; 21(1):50. PubMed ID: 31412875
[TBL] [Abstract][Full Text] [Related]
12. A validation study of the European Society of Cardiology guidelines for risk stratification of sudden cardiac death in childhood hypertrophic cardiomyopathy.
Norrish G; Ding T; Field E; McLeod K; Ilina M; Stuart G; Bhole V; Uzun O; Brown E; Daubeney PEF; Lota A; Linter K; Mathur S; Bharucha T; Kok KL; Adwani S; Jones CB; Reinhardt Z; Omar RZ; Kaski JP
Europace; 2019 Oct; 21(10):1559-1565. PubMed ID: 31155643
[TBL] [Abstract][Full Text] [Related]
13. [Feasibility of the 2014 European guidelines risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy in Chinese patients].
Zhu SH; Li Y; Huang W; Jiang H; Li SN; Chen L; Huang S; Yu HS; Xu B
Zhonghua Xin Xue Guan Bing Za Zhi; 2017 May; 45(5):404-408. PubMed ID: 28511325
[No Abstract] [Full Text] [Related]
14. International External Validation Study of the 2014 European Society of Cardiology Guidelines on Sudden Cardiac Death Prevention in Hypertrophic Cardiomyopathy (EVIDENCE-HCM).
O'Mahony C; Jichi F; Ommen SR; Christiaans I; Arbustini E; Garcia-Pavia P; Cecchi F; Olivotto I; Kitaoka H; Gotsman I; Carr-White G; Mogensen J; Antoniades L; Mohiddin SA; Maurer MS; Tang HC; Geske JB; Siontis KC; Mahmoud KD; Vermeer A; Wilde A; Favalli V; Guttmann OP; Gallego-Delgado M; Dominguez F; Tanini I; Kubo T; Keren A; Bueser T; Waters S; Issa IF; Malcolmson J; Burns T; Sekhri N; Hoeger CW; Omar RZ; Elliott PM
Circulation; 2018 Mar; 137(10):1015-1023. PubMed ID: 29191938
[TBL] [Abstract][Full Text] [Related]
15. Left intraventricular pressure gradient in hypertrophic cardiomyopathy patients receiving implantable cardioverter-defibrillators for primary prevention.
Yazaki K; Suzuki A; Shiga T; Minami Y; Arai K; Ashihara K; Shoda M; Hagiwara N
BMC Cardiovasc Disord; 2021 Feb; 21(1):106. PubMed ID: 33607967
[TBL] [Abstract][Full Text] [Related]
16. Evolution of risk stratification and sudden death prevention in hypertrophic cardiomyopathy: Twenty years with the implantable cardioverter-defibrillator.
Maron BJ; Rowin EJ; Maron MS
Heart Rhythm; 2021 Jun; 18(6):1012-1023. PubMed ID: 33508516
[TBL] [Abstract][Full Text] [Related]
17. Validation of the HCM Risk-SCD model in patients with hypertrophic cardiomyopathy following alcohol septal ablation.
Liebregts M; Faber L; Jensen MK; Vriesendorp PA; Hansen PR; Seggewiss H; Horstkotte D; Adlova R; Michels M; Bundgaard H; Ten Berg JM; Veselka J
Europace; 2018 Sep; 20(FI2):f198-f203. PubMed ID: 29016960
[TBL] [Abstract][Full Text] [Related]
18. Implantable cardioverter defibrillators for primary prevention of sudden death in hypertrophic cardiomyopathy.
Konstantinou DM; Efthimiadis GK; Vassilikos V; Paraskevaidis S; Pagourelias E; Maron BJ; Karvounis H
J Cardiovasc Med (Hagerstown); 2016 Jun; 17(6):433-9. PubMed ID: 26885981
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the new risk prediction model (HCM Risk-SCD) and classic risk factors for sudden death in patients with hypertrophic cardiomyopathy and defibrillator.
Ruiz-Salas A; García-Pinilla JM; Cabrera-Bueno F; Fernández-Pastor J; Peña-Hernández J; Medina-Palomo C; Barrera-Cordero A; De Teresa E; Alzueta J
Europace; 2016 May; 18(5):773-7. PubMed ID: 25855675
[TBL] [Abstract][Full Text] [Related]
20. Cardiopulmonary exercise test and sudden cardiac death risk in hypertrophic cardiomyopathy.
Magrì D; Limongelli G; Re F; Agostoni P; Zachara E; Correale M; Mastromarino V; Santolamazza C; Casenghi M; Pacileo G; Valente F; Musumeci B; Maruotti A; Volpe M; Autore C
Heart; 2016 Apr; 102(8):602-9. PubMed ID: 26849900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
